Last reviewed · How we verify
NCT02597660
A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy
Phase 2 trial testing Somatropin in Tendinopathy. Withdrawn.
1 December 2020
Quick facts
| Lead sponsor | Hospital for Special Surgery, New York |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | basic science |
| Start date | 1 May 2020 |
| Primary completion | 1 December 2020 |
| Estimated completion | 1 December 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Somatropin (Somatropin) — full drug profile →
- Bacteriostatic saline — full drug profile →
- Progressive exercise program
- Patellar tendon biopsy
Conditions studied
- Tendinopathy — all drugs for Tendinopathy →
Sponsor
Hospital for Special Surgery, New York
Who can join
Adults 18 to 50, any sex, with Tendinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patellar tendinopathy is one of the most frequent causes of non-traumatic knee pain and reduced function in patients. Standard treatment options for patellar tendinopathies include non-steroidal anti-inflammatory drugs, corticosteroids, cryotherapy, manual therapy, eccentric exercises, and ultrasound. Unfortunately many patients fail to respond to these therapies and return to normal activity levels, and recurrence rates for those who do respond are unacceptably high. Many patients who fail to respond display persistent degenerative changes on imaging studies suggesting a failure to regenerate the pathological tissue. Developing new therapies that can directly promote the synthesis of new, healthy extracellular matrix tissue could therefore address an important therapeutic need and make a substantial improvement in our ability to effectively treat patellar tendinopathy and reduce recurrence rates. Somatropin (human growth hormone of recombinant DNA origin) has been shown to increase protein synthesis and matrix production when delivered directly into the tendon. This study will evaluate the ability of somatropin to improve clinical outcomes and tissue quality in patients with chronic tendinopathy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Exercise for patellar tendinopathy.
Lopes AD, Rizzo RR, Hespanhol L, Costa LO, et al · · 2025 · cited 2× · PMID 40421598 · DOI 10.1002/14651858.cd013078.pub2
Verify or expand the search:
- PubMed search for NCT02597660
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Somatropin
Trials testing the same drug.
- NCT04867317 — Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficien · Phase 3 · recruiting
- NCT06103513 — Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children · Phase 3 · unknown
- NCT05900661 — The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders · Phase 2, PHASE3 · unknown
- NCT05382637 — Growth Hormone in a Patient With a Dominant-Negative GHR Mutation · Phase 2 · active not recruiting
- NCT04615273 — A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product · Phase 3 · completed
Other recruiting trials for Tendinopathy
Currently open trials in the same condition.
- NCT07231471 — Platelet Rich Plasma for Musculoskeletal Conditions · NA · recruiting
- NCT07025668 — The Effectiveness of Different Exercise Approaches in Biceps Brachii Long Head Tendinopathy · NA · recruiting
- NCT06095050 — Embolization Treatment of Chronic Refractory Shoulder Tendinopathy · NA · recruiting
- NCT06639308 — Eendoscopic Versus Open Flexor Hallucis Longus Transfer in Managing Various Tendon Achilles Disorders · NA · active not recruiting
- NCT06160427 — Connective Tissue Matrix for Rotator Cuff Tendinopathy · Phase 4 · active not recruiting
Other Hospital for Special Surgery, New York trials
Trials by the same sponsor.
- NCT07226700 — Suzetrigine in Total Hip Arthroplasty · Phase 3 · recruiting
- NCT06567873 — Gastric Ultrasound Assessment for Patients Taking Cannabis · completed
- NCT07217964 — Natural Matrix Protein · enrolling by invitation
- NCT06798493 — CSS-SR Validation Study · enrolling by invitation
- NCT06180486 — Mindfulness Meditation Intervention Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02597660 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital for Special Surgery, New York
- Last refreshed: 31 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02597660.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing